TCGA-AR-A24V-01A-21R-A169-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 107
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- INTERFERON_ALPHA_RESPONSE+0.540
- ANGIOGENESIS+0.460
- INTERFERON_GAMMA_RESPONSE+0.420
- UV_RESPONSE_DN+0.390
- HEDGEHOG_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.380
- HYPOXIA+0.360
- IL6_JAK_STAT3_SIGNALING+0.360
- INFLAMMATORY_RESPONSE+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.380
- E2F_TARGETS-0.340
- MYC_TARGETS_V1-0.320
- OXIDATIVE_PHOSPHORYLATION-0.310
- G2M_CHECKPOINT-0.300
- DNA_REPAIR-0.250
- PEROXISOME-0.250
- ADIPOGENESIS-0.180
- FATTY_ACID_METABOLISM-0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278883 | — | — | 0.909 |
| 2 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.906 |
| 3 | ERR2208918 | — | — | 0.904 |
| 4 | TCGA-DK-A1AB-01A-11R-A13Y-07 | — | — | 0.899 |
| 5 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.899 |
| 6 | MDT-AP-3277 | Med | Medulloblastoma | 0.896 |
| 7 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.892 |
| 8 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.889 |
| 9 | SRR934720 | — | — | 0.885 |
| 10 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |